Determination of Chemical Irritation Potential Using a Defined Gene Signature Set on Tissue-Engineered Human Skin Equivalents.
CA, cinnamaldehyde
CAP, capsaicin
CON, control
Co-DEA, cocamide diethanolamine
Co-MEA, cocamide monoethanolamine
H2O, water
HDF, human dermal fibroblast
HSE, human skin equivalent
KC, keratinocyte
LA, lactic acid
LDA, linear discrimination analysis
LDH, lactate dehydrogenase
MMP, matrix metalloproteinase
MP, methylparaben
N-LA, neutralized lactic acid
PCA, principal component analysis
TEER, transepithelial electrical resistance
Journal
JID innovations : skin science from molecules to population health
ISSN: 2667-0267
Titre abrégé: JID Innov
Pays: Netherlands
ID NLM: 101776173
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
11
01
2021
revised:
24
02
2021
accepted:
25
02
2021
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
16
12
2021
Statut:
epublish
Résumé
There are no physical or visual manifestations that define skin sensitivity or irritation; a subjective diagnosis is made on the basis of the evaluation of clinical presentations, including burning, prickling, erythema, and itching. Adverse skin reaction in response to topically applied products is common and can limit the use of dermatological or cosmetic products. The purpose of this study was to evaluate the use of human skin equivalents based on immortalized skin keratinocytes and evaluate the potential of a 22-gene panel in combination with multivariate analysis to discriminate between chemicals known to act as irritants and those that do not. Test compounds were applied topically to full-thickness human skin equivalent or human ex vivo skin and gene signatures determined for known irritants and nonirritants. Principle component analysis showed the discriminatory potential of the 22-gene panel. Linear discrimination analysis, performed to further refine the gene set for a more high-throughput analysis, identified a putative seven-gene panel (
Identifiants
pubmed: 34909715
doi: 10.1016/j.xjidi.2021.100011
pii: S2667-0267(21)00011-4
pmc: PMC8659397
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100011Informations de copyright
© 2021 The Authors.
Références
Toxicol Appl Pharmacol. 2010 Jun 15;245(3):281-90
pubmed: 20307559
Nat Neurosci. 2006 May;9(5):628-35
pubmed: 16617338
Exp Dermatol. 2018 Mar;27(3):238-244
pubmed: 29280518
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6885-9
pubmed: 10359808
Exp Dermatol. 2012 Feb;21(2):156-8
pubmed: 22229444
Biomaterials. 2015 May;51:216-225
pubmed: 25771012
Cell Biol Toxicol. 1995 Aug;11(3-4):167-71
pubmed: 8564646
J Appl Toxicol. 2016 Sep;36(9):1129-36
pubmed: 26691653
Br J Dermatol. 2001 Jul;145(1):3-9
pubmed: 11453900
Toxicol In Vitro. 2013 Apr;27(3):1127-34
pubmed: 23063874
Toxicol In Vitro. 2016 Apr;32:248-60
pubmed: 26795242
J Immunol. 2005 Apr 15;174(8):5047-56
pubmed: 15814736
Stem Cell Rev Rep. 2012 Sep;8(3):1030-4
pubmed: 22134928
Contact Dermatitis. 2006 Jul;55(1):1-14
pubmed: 16842547
Mol Cell Biol. 2000 Feb;20(4):1436-47
pubmed: 10648628
Cell. 2010 Apr 16;141(2):331-43
pubmed: 20403327
Arch Dermatol Res. 2012 May;304(4):289-303
pubmed: 22271211
Regul Toxicol Pharmacol. 2014 Aug;69(3):529-45
pubmed: 24928565
J Appl Toxicol. 2013 Dec;33(12):1407-15
pubmed: 22886929
J Invest Dermatol. 2011 Feb;131(2):418-25
pubmed: 21068755
Exp Dermatol. 2015 Aug;24(8):598-604
pubmed: 25865800
Toxicol In Vitro. 2006 Aug;20(5):767-73
pubmed: 16311011
Front Med (Lausanne). 2019 May 21;6:108
pubmed: 31165070
Tissue Eng Part C Methods. 2016 Dec;22(12):1108-1117
pubmed: 27846777
Hum Cell. 2018 Jan;31(1):1-9
pubmed: 28916968
Acta Biomater. 2018 Dec;82:93-101
pubmed: 30316025
Toxicol In Vitro. 2015 Aug;29(5):901-16
pubmed: 25820135
Toxicol In Vitro. 2019 Jun;57:164-173
pubmed: 30851411
Ann Dermatol. 2010 Aug;22(3):290-9
pubmed: 20711265
Tissue Eng Part A. 2014 Aug;20(15-16):2180-8
pubmed: 24716723
Toxicol In Vitro. 2018 Feb;46:77-85
pubmed: 28941582
Regul Toxicol Pharmacol. 2018 Oct;98:209-214
pubmed: 30056248
Exp Dermatol. 2009 May;18(5):417-23
pubmed: 19382311
Toxicol Sci. 2004 Oct;81(2):332-43
pubmed: 15254333
Oncotarget. 2016 Aug 23;7(34):55863-55889
pubmed: 27331412
Nat Rev Immunol. 2013 Sep;13(9):679-92
pubmed: 23954936
Mol Pharmacol. 2019 Sep;96(3):393-400
pubmed: 31308264
J Mol Med (Berl). 2009 Nov;87(11):1053-60
pubmed: 19705082
Tissue Eng Part A. 2016 Jan;22(1-2):111-22
pubmed: 26415037
Toxicol In Vitro. 2014 Dec;28(8):1482-97
pubmed: 25172300
Toxicol In Vitro. 2017 Apr;40:11-25
pubmed: 27965148
Acta Derm Venereol. 2017 Jan 4;97(1):4-6
pubmed: 26939643
Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):373-82
pubmed: 26439184
Eur J Cell Biol. 2012 Oct;91(10):765-73
pubmed: 22857950
Toxicol In Vitro. 2006 Aug;20(5):774-84
pubmed: 16337770
Exp Dermatol. 2010 Aug;19(8):e310-3
pubmed: 20002170
J Invest Dermatol. 2010 Sep;130(9):2201-10
pubmed: 20428187
Toxicol In Vitro. 2013 Dec;27(8):2213-24
pubmed: 23999411
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Toxicol In Vitro. 2011 Apr;25(3):733-44
pubmed: 21195160
Arch Toxicol. 2001 Feb;74(12):768-74
pubmed: 11305779
J Cell Sci. 2005 Aug 1;118(Pt 15):3471-85
pubmed: 16079289
Toxicol Appl Pharmacol. 2010 Dec 1;249(2):178-87
pubmed: 20840853
Science. 2002 Jun 14;296(5575):2046-9
pubmed: 12016205
Pain. 2018 Oct;159(10):1989-2001
pubmed: 29847470
J Biol Chem. 2012 Jul 27;287(31):25905-16
pubmed: 22679014
J Invest Dermatol. 1997 Sep;109(3):334-9
pubmed: 9284101
Biomaterials. 1998 Sep;19(18):1689-94
pubmed: 9840004
J Dermatol Sci. 2001 Jun;26(2):85-93
pubmed: 11378323
Br J Dermatol. 1977 May;96(5):461-73
pubmed: 871381
J Dermatol Sci. 2018 Nov;92(2):172-180
pubmed: 30220530
Cancer Invest. 2008 Oct;26(8):843-51
pubmed: 18798064
Toxicol Appl Pharmacol. 2010 Jun 15;245(3):352-60
pubmed: 20382172
Contact Dermatitis. 2005 Aug;53(2):93-9
pubmed: 16033403
Toxicol In Vitro. 2015 Jun;29(4):787-802
pubmed: 25724174
J Leukoc Biol. 2011 Nov;90(5):1027-33
pubmed: 21697260